Back to Hematology
Hematologyv2008Evidence-Based

Mantle Cell Lymphoma International Prognostic Index (MIPI)

Predicts survival in mantle cell lymphoma patients using age, performance status, lactate dehydrogenase level, and white blood cell count. More specific to mantle cell lymphoma than the International Prognostic Index (IPI). Stratifies patients into low, intermediate, and high risk categories for prognostic planning and treatment decisions.

Clinical Input Parameters

years
Range: 18 — 100 years
U/L
Range: 50 — 10000 U/L
U/L
Range: 150 — 400 U/L
×10³/μL
Range: 1 — 500 ×10³/μL
%
Range: 0 — 100 %
Clinical Assessment
Awaiting Parameters
mipi score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

MIPI = (0.03535 × age in years) + 0.6978 (if ECOG PS 2-4) + [1.367 × log10(LDH/ULN)] + [0.9393 × log10(WBC in ×10³/μL)]. MIPIb (biological MIPI) = MIPI + (0.02142 × Ki-67 index %) when Ki-67 is available.

Clinical Pearls & Practice Notes

  • Developed specifically for mantle cell lymphoma, more specific than the International Prognostic Index (IPI)
  • Based on 455 advanced stage MCL patients treated in European clinical trials
  • Approximately 18% of original cohort received high-dose therapy with stem cell transplantation
  • Ki-67 proliferation index provides additional prognostic information when available (MIPIb)
  • Most mantle cell lymphoma patients require treatment at diagnosis regardless of risk group
  • May help guide treatment intensity and consideration for stem cell transplantation
  • Should be used in conjunction with other clinical factors and patient preferences
  • Performance status significantly impacts prognosis independent of other factors
  • LDH and WBC reflect disease burden and biological activity
  • Age remains an important prognostic factor even in the era of modern therapy
  • Risk stratification may influence clinical trial eligibility and treatment selection
  • Regular reassessment during treatment course is important for treatment modifications

Evidence & Literature Citations

  1. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008 Jan 15;111(2):558-65. doi: 10.1182/blood-2007-06-095331.
  2. Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, Trneny M, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014 May 1;32(13):1338-46. doi: 10.1200/JCO.2013.52.2466.
  3. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008 Oct 1;112(7):2687-93. doi: 10.1182/blood-2008-03-147025.

Score Interpretation Ranges

Low Risk0 – 5.7 pts

Low risk for poor prognosis

Intermediate Risk5.7 – 6.2 pts

Intermediate risk for poor prognosis

High Risk6.2 – 20 pts

High risk for poor prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.